|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|

|  |  |
| --- | --- |
|

|  |
| --- |
|   |

 |
|

|  |
| --- |
|  |
| PSNC Newsletter |
| Friday 20th January 2023 |

 |
|  |
|

|  |  |  |
| --- | --- | --- |
|  |  |  |
|  | This newsletter from PSNC is sent on Mondays, Wednesdays and Fridays. It contains important information for those that work in the community pharmacy sector.In this update: Keeping pharmacy in the press; evaluation of PQS NSAID audits; dispensing and supply updates.Influencing on behalf of pharmaciesPSNC is extremely concerned about the immense pressures that community pharmacy contractors are continuing to face, and the ongoing threat of more permanent closures. As part of our work to ensure that this critical issue remains high on the Government's agenda, we have been regularly briefing national journalists about the precarious state of the sector. As a recent example, Chief Executive Janet Morrison, was quoted in [**iNews today**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=0ef6935b07&e=d19e9fd41c), talking about the funding cuts imposed on community pharmacies over the last seven years and repeating calls for urgent Government action to protect pharmacies and put them on a sustainable footing.As you may have seen earlier this week, PSNC has also announced plans to work with other national pharmacy bodies to mobilise support for pharmacy through a co-ordinated influencing campaign.[**Learn more about the #saveourpharmacies campaign**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=51ceef28ec&e=d19e9fd41c) More than 15,000 patients referred as part of PQS NSAID auditsAn evaluation of the 2018/19 and 2019/20 non-steroidal anti-inflammatory drugs (NSAID) Pharmacy Quality Scheme (PQS) audits has been published. The evaluation shows that community pharmacy teams spoke to **over 165,000 patients** during the two audit periods and referred **more than 15,000 patients** at risk of preventable harm from NSAIDs to prescribers for review. [**Find out more**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=4269cf8886&e=d19e9fd41c). Dispensing and Supply Updates**January Price Concessions Second Update**The Department of Health and Social Care (DHSC) has granted an updated list of price concessions for January 2023. **Please note this is not the final list**. [**See the January price concessions list**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=77bc1d5154&e=d19e9fd41c).**Medicines Recall Notice**The Medicines and Health products Regulatory Agency (MHRA) has issued a class 3 medicines recall for Lacidipine 4 mg Film-Coated Tablets. The recall is a precautionary measure due to the presence of an unknown solvent-like odour. [**Learn more about this recall**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=319ea83b2b&e=d19e9fd41c). |  |
|  |  |  |

 |

 |
|

|  |  |  |
| --- | --- | --- |
|

|  |
| --- |
| Pharmaceutical Services Negotiating Committee    14 Hosier Lane, London, EC1A 9LQTel: 0203 1220 810 | Email: **info@psnc.org.uk**  |
|  |

 |

 |

